TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00732732

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green banana powder
Description: Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
Study: NCT03426995

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3358699
Description: GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3358699
Description: GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3358699
Description: GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3358699
Description: GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3358699
Description: GSK3358699, will be administered from 1 mg to 45 mg as an oral solution (1 to 10 mg) or as a capsule (3 to 45 mg), in Part A, B and Part C once daily.
Study: NCT01996098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month Icotinib
Description: 125 mg three times daily (375 mg per day) by mouth for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12-month icotinib
Description: 125 mg three times daily (375 mg per day) by mouth for 12 months
Study: NCT01738295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Study: NCT01202175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Oral nebivolol 2.5-5mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebivolol
Description: Oral nebivolol 2.5-5mg once daily
Study: NCT03888469

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Investigational daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses
Description: Commercially available daily disposable soft contact lenses
Study: NCT02828293

Intervention type: OTHER
Intervention: Dynamic videofluoroscopic analysis
Description: Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.

Intervention type: OTHER
Intervention: Dynamic videofluoroscopic analysis
Description: Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.

Intervention type: OTHER
Intervention: Dynamic videofluoroscopic analysis
Description: Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
Study: NCT03339609

Intervention type: DIAGNOSTIC_TEST
Intervention: Uroflow/EMG
Description: Uroflow measurement with superficial EMG testing of the pelvic floor
Study: NCT03426995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
Study: NCT03339609

Intervention type: DIAGNOSTIC_TEST
Intervention: US
Description: Ultrasound of post void residual urine
Study: NCT03426995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GM-CSF
Description: The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GM-CSF
Description: The GM-CSF will be administered as an intravenous infusion to subjects as 60 microgram per meter\^2 in Part A (Day 1) and Part C (Day 14).This will be administered for 2 hours approximately, no later than 24 hours post -dose of the GSK3358699 or placebo in Part C
Study: NCT01487967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preference and Goal Instrument
Description: Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
Study: NCT02632045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE-011
Description: 600 mg capsule (3x 200 mg capsules)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: 500 mg injection
Study: NCT03499067

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Test lens
Description: Contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: Contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control lens
Description: Contact lens
Study: NCT01417403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT03499067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control lens
Description: Contact lens
Study: NCT04658966

Intervention type: OTHER
Intervention: administration of a self-questionnaire
Description: Women will have to fill in an online self questionnaire on pre-eclampsia

Intervention type: OTHER
Intervention: administration of a self-questionnaire
Description: Women will have to fill in an online self questionnaire on pre-eclampsia
Study: NCT02892045

Intervention type: DEVICE
Intervention: MMG
Description: neuromuscular monitoring device
Study: NCT00498147

Intervention type: OTHER
Intervention: ADEC Program
Description: Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.

Intervention type: OTHER
Intervention: ADEC Program
Description: Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
Study: NCT03908125

Intervention type: DEVICE
Group type: OTHER
Intervention: Eversense® CGM system
Description: Continuous Glucose monitoring device that lasts up to 90 days
Study: NCT03797807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MINST
Description: A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential
Study: NCT02123199

Intervention type: DRUG
Intervention: Indacaterol (Onbrez®) /QAB149
Study: NCT02142686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 80
Description: After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 50
Description: After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filling pressure 30
Description: After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
Study: NCT03791866

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Enteral nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Enteral nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Enteral nutrition
Study: NCT02072291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: PO Nifedipine 5mg single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: PO Nifedipine 5mg single dose
Study: NCT02142166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker in serum, liquor, micro-dialysate
Description: Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biomarker in serum and in liquor
Description: Single analysis of biomarker in serum and liquor
Study: NCT03797807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MINST
Description: A non-surgical minimally invasive treatment protocol, named MINST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIST
Description: A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MIST
Description: A minimally invasive surgical treatment protocol, named MIST, has been proposed for the treatment of periodontal intrabony defects, in order to minimize patient discomfort and maximize the healing potential

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GTI subgroup (Geometrical/Thermal Imaging)
Description: Geometrical/Thermal Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: GTI subgroup (Geometrical/Thermal Imaging)
Description: Geometrical/Thermal Imaging
Study: NCT01332487

Intervention type: DRUG
Intervention: 5ARI + AB
Description: 5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin

Intervention type: DRUG
Intervention: 5ARI + AB
Description: 5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
Study: NCT02380339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psych-Educational session and virtual reality
Description: Psych-Educational session and virtual reality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psych-Educational and BF sessions
Description: Psych-Educational and BF sessions
Study: NCT03426995

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LPS
Description: LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: LPS
Description: LPS will be administered as an intravenous injection to subjects not exceeding 0.75 nanogram per kilogram in Part A (Day 1) and Part C (Day 14). This will be administered no later than 24 hours post -dose of the GSK3358699 or placebo in Part C.
Study: NCT01170728

Intervention type: DEVICE
Intervention: Coloplast Virtue® Male Sling
Description: The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
Study: NCT01414569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Singe dose preoperatively in 100 ml saline intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Singe dose preoperatively in 100 ml saline intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Singe dose preoperatively in 100 ml saline intravenously
Study: NCT05156580

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention

Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study without any intervention
Study: NCT01095588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg Avanafil
Description: 2 X 100mg tablets avanafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets
Study: NCT01790334

Intervention type: OTHER
Intervention: Ultrasonography

Intervention type: OTHER
Intervention: Ultrasonography

Intervention type: OTHER
Intervention: Ultrasonography
Study: NCT04582032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen (KETAVEL 50 mg/2 ml)
Description: intravenous dexketoprofen (KETAVEL 50 mg/2 ml)

Intervention type: DRUG
Group type: OTHER
Intervention: Saline (Isotonic Saline Solution 0.9% )
Description: intravenous 2 ml of saline
Study: NCT03426995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
Study: NCT01605851

Intervention type: DEVICE
Group type: OTHER
Intervention: Closure, Foramen Ovale
Study: NCT01059656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
Study: NCT03426995

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cantharidin
Description: This will be applied as a topical application with 0.7% cantharidin liquid which will be diluted with acetone to 0.2%.
Study: NCT02632045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 600 mg capsule (3x 200 mg capsules)
Study: NCT02570815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
Study: NCT02588027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmacy formulated placebo
Study: NCT03832907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM - Continues Glucose Monitoring sensor system
Description: A blinded factory-calibrated continues glucose monitoring sensor system Dexcom G6 will be placed shortly after admission. Two CGM devices will be inserted in all patients - one in the abdomen and one in the arm to also assess differences in blood glucose readings between upper extremity and abdominal insertion sites. Information on CGM readings will be collected daily during the hospital stay and after hospital discharge for 10 days using the Dexcom Studio software to download the Dexcom receiver data.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: POC BG - Point-of-Care Blood Glucose monitoring
Description: Standard of care - bedside point-of-care (POC) capillary blood glucose (BG) monitoring will be done before meals and bedtime daily during the hospital stay and after hospital discharge for 10 days.
Study: NCT03790475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offering a choice for colorectal cancer screening
Description: Persons randomized to the multiple options screening strategy group will receive a postal invitation offering a choice between FIT and colonoscopy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Offering an alternative colorectal cancer screening method
Description: Persons randomized to the sequential screening strategy group will receive a postal invitation to the colonoscopy followed by a postal invitation for screening using FIT for non-responders and subjects refusing colonoscopy.
Study: NCT04555772

Intervention type: OTHER
Intervention: factors evaluation
Description: They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.

Intervention type: OTHER
Intervention: factors evaluation
Description: They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.

Intervention type: OTHER
Intervention: factors evaluation
Description: They investigated mortality and morbidity in patients who underwent emergency operation within 24 hours after traumatic brain injury.
Study: NCT00812968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
Study: NCT03740126

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole body 18F-FDG PET/CT
Description: In the experimental arm (A), an FDG-PET/CT scan will replace the CT-scan at 6, 12, 18 and 24 months post-treatment. A standard CT-scan will be performed at 3, 9, 15 and 21 months post-treatment. All patients will be asked for a blood sample for liquid biopsy and to fill in a quality of life questionnaire, concurrently every 3 months.